1Cersosimo RJ.Irinotecan a new antine oplastic agent for the management of colorectal cancer[J].ann pharmacother,1998,32 (12):1324-1333.
2Ma MK,Mcleod HL.Lessons learned from the irinotecan metabolic pathway[J].Curr Med Chem,2003,10(1):41-49.
3Slatter JG,Schaaf LJ,Sams JP,et al.Pharmacokinetics metabolism,and excretion of irinotecan (CPT11) following Ⅰ.Ⅴ.infusion of[14C] CPT11 in cancer patients[J].Drug Metab Dispos,2000,28(4):S423 -433.
5Fukuda M,Oka M,Soda H.Phasell study of irinotecan combined with carboplatin in previously untreated non small cell lung cancer[J].Cancer Chemother Pharmacol,2004,54(6):573 -577.
6NegoroS,MasudaN,Takada Y.Radomised phase Ⅲ trial of irinotecan combined with cisplatin for advanced non small cell lung cancer[J].BrJ Cancer,2003,88 (3):335-341.
7Langer CJ.The global role of irinotecan in the treatment of lung cancer:2003 update[J].Oncology (Hunting),2003,17(7Suppl 7):30 -40.
1[1]VANHOEFER U,HARSTRICK A,KOHNE CH,et al.Phase Ⅰstudy of a weekly schedule of irinotecan,high-dose leucovorin,and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer[J].J Clin Oncol,1999,17(3):907-913.
2[2]DUCREUX M,YCHOU M,SEITZ JF,et al.Irinotecan combined with bolus fluorouracil,continuous infusion fluorouracil,and high-dose leucovorin every two weeks (LV5FUZ regimen):a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colcorectal cancer[J].J Clin Oncol,1999,17(9):2901-2908.
3[3]SALTZ LB,ELFRING GL,MILLER LL.Weekly irinotecan (CPT-11),leucovorin(LV) and fluorouracil is superior to dairly X5LV/FU in patients CPTs with preciously untreated matastatic colorectal cancer(CRC)[J].Proc ASCO,1999,18:233.
4[4]AGRAWAL S,KANDIMALLA ER,YU D,et al.Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides[J].Int J Oncol,2001,18(5):1061-1069.
5[5]TANAKA H,UMEKAWA T,NAGAO K,et al.Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in platinum-and paclitaxel-resistant epithelial ovarian cancer:case reports[J].Eur J Gynaecol Oncol,2003,24(3-4):337-340.
6[6]GERSHENSON DM.Irinotecan in epithelial ovarian cancer[J].Oncology (Huntingt),2002,16(5 Suppl 5):29-31.
7[7]SUGIYAMA T,USHIJIMA K,KAMURA T.New regimens for the treatment of gynecologic cancers[J].Gan To Kagaku Ryoho,2000,27(3):375-381.
8[8]van CUTSEM E,CUNNINGHAM D,TEN BOKKEL HUININK WW,et al.Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-FU[J].Eur J Cancer,1999,35(1),54-59.
9[9]MARKMAN M,ZANOTTI K,WEBSTER K,et al.Toxicity associated with carboplatin/paclitaxel/irinotecan use in advanced ovarian cancer:preliminary analysis[J].Oncology (Huntingt),2003 ,17(5 Suppl 5):34-35.
